BIIB News 342.58 08/21/2014 04:44:56 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 342.58 $BIIB

What Investors Gain from Large, Mid & Small-Cap Growth Funds - Mutual Fund Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:02PM CDT
For investors looking to invest in growth funds, we will suggest here the top growth funds from each market capitalization. These funds carry a Zacks Mutual Fund Rank #1 (Strong Buy) as we expect the funds to outperform its peers in the future

Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.

US Orphan Drug Clinical Pipeline Insight 2014 - New Report on the $49 Billion Industry
M2 - Wed Aug 20, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q26z36/us_orphan_drug) has announced the addition of the "US Orphan Drug Clinical Pipeline Insight 2014" report to their offering. In 2013, the US market for orphan drugs was estimated worth US$ 49 Billion. With factors like government support, high profitability and many more, this market is expected to surpass US$ 60 Billion by 2018. The orphan drugs enjoy significant competitive advantages owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs. In US, the research & development of orphan drugs is facilitated by public programs, government regulations, and policies. The major incentives for research & development of orphan drug include grants, research support, fee waivers, tax incentives, and orphan drug market exclusivity. In a highly specialized market like that of orphan drugs, though the impact of market exclusivity in the US has been positive yet relatively modest, a special platform for continued orphan drug development has been laid down by the economic incentives and public support mechanisms. US Orphan Drug Pipeline Insight 2014 - Report Highlight: - US Orphan Drug Market Insight & Orphan Drug Designation Criteria - Reimbursement Policy & FDA Regulatory Framework - US Orphan Drug Pipeline by Phase, Indication & Company - Marketed Orphan Drug Clinical Insight - US Orphan Drug Clinical Pipeline: 570 Drugs - Marketed Orphan Drugs in US: 203 Drugs - Majority Orphan Drugs in PHASE-II Development: 207 Drugs Key Topics Covered: 1. Introduction to US Orphan Market - Market Overview - Clinical Pipeline Overview 2. US Orphan Drug Regulatory Framework - Criteria for Orphan Drug Designation - Reimbursement Policy for Orphan Drugs - FDA Regulation 3. US Orphan Drug Clinical Pipeline by Phase, Indication & Company - Unknown - Research - Preclinical - Clinical - Phase-I - Phase-I/II - Phase-II - Phase-II/III - Phase-III - Preregistration - Registered 4. Marketed Orphan Drugs Clinical Insight by Indication & Company 5. Suspended & Discontinued Orphan Drugs in Clinical Pipeline by Phase, Indication & Company - No development reported - Discontinued - Market Withdrawal - Suspended 6. Competitive Landscape - Alexion - Biogen Idec - Bristol Myers Squibb - Celgene - Eli Lilly - Glaxosmithkline - Merck - Novartis Pharmaceuticals - Pfizer - Roche - Rare Disease Therapeutics - Sanofi For more information visit http://www.researchandmarkets.com/research/q2...rphan_drug

Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck
PR Newswire - Wed Aug 20, 8:20AM CDT
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Merck (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5855-100free.

Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 19, 12:20PM CDT
Plegridy's less frequent dosing schedule could help it gain share from other beta interferon treatments.

Biogen's buy rating reaffirmed
at Investor's Business Daily - Mon Aug 18, 5:40PM CDT
The biotech's overweight or buy rating was reaffirmed by Morgan Stanley on the FDA's approval of Biogen's (BIIB) new Plegridy drug for people with multiple sclerosis on Fri. The new treatment is a long-lasting form of the company's Avonex drug and...

Why Biogen Idec (BIIB) Stock Is Gaining Today
at The Street - Mon Aug 18, 10:44AM CDT
Biogen Idec (BIIB) shares are climbing on Monday after the company's relapsing multiple sclerosis drug treatment, Plegridy, was approved by the FDA.

Isis Pharmaceuticals earns USD2m for advancement of ISIS-SMN Rx in children with SMA from Biogen Idec
M2 - Mon Aug 18, 7:20AM CDT
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Friday the receipt of a USD2m milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).

Biogen Idec awarded US FDA approval for PLEGRIDY for treating multiple sclerosis
M2 - Mon Aug 18, 5:33AM CDT
Medicine company Biogen Idec (NasdaqGS:BIIB) reported on Friday the receipt of approval from the US Food and Drug Administration (FDA) for treating people with relapsing forms of multiple sclerosis (RMS) with the new subcutaneous injectable therapy, PLEGRIDY.

FDA approves Biogen's MS drug Plegridy
AP - Fri Aug 15, 6:27PM CDT
CAMBRIDGE, Mass. (AP) — Biogen Idec says that federal regulators have approved the specialty drugmaker's new treatment for people with relapsing forms of multiple sclerosis.

Biogen Idec's PLEGRIDY(TM)(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
Business Wire - Fri Aug 15, 5:44PM CDT
--a^' Only Pegylated Interferon in MS, Dosed Once Every Two Weeks -

Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 1.62% Rise
Comtex SmarTrend(R) - Fri Aug 15, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $330.70 to a high of $343.03. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $338.51 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Biogen Idec Rises 1.62% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Aug 15, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $330.70 to a high of $343.03. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $338.51 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Today's Momo Momentum Stock Is Biogen Idec (BIIB)
at The Street - Fri Aug 15, 8:49AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate

Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
PR Newswire - Fri Aug 15, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).

Global Biological Drugs Market 2014 - 2020 - Industry Analysis for the $161.056 Million Industry
M2 - Fri Aug 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjz57l/biological_drugs) has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach USD 287,139.7 million by 2020 The report provides in-depth analysis and estimation of the biological drugs market from 2014 to 2020, considering 2013 as the base year for calculation. Additionally, data pertaining to current market dynamics including market drivers, restraints, trends and recent developments has been provided in the biological drugs market report. The global biological drugs market is categorized based on therapeutic protein, monoclonal antibody (mAb), vaccine and geography. The therapeutic protein segmentation is further sub-segmented into Enbrel, Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen, Levemir, Victoza, Betaseron, Neupogen, and Eylea. The mAb segment comprises Humira, Remicade, Rituxan, Avastin, Herceptin and Lucentis. The vaccine segment is further sub-segmented into Prevnar 13, Gardasil, Fluzone, Varivax and Cervarix. Globally, the biological drugs market is witnessing a significant growth due to increasing prevalence of various chronic diseases, as the demand for biological drugs is increasing with the rise in the global geriatric population. The biological drugs are used in the treatment and prevention of various diseases, such as blood related diseases, cancer, auto-immune diseases and other medical disorders. Additionally, various government associations are promoting the usage of biological drugs. Moreover, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market. North America is the largest market for biological drugs. Enbrel is the largest and fastest growing therapeutic protein. In monoclonal antibody (mAb), Humira is the largest and fastest growing mAb. Prevnar 13 is the largest and fastest growing vaccine. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Biological Drugs Market - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Forces Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis, by Therapeutic Protein Chapter 8 Segment Analysis, by mAb Chapter 9 Segment Analysis, by Vaccine Chapter 10 Regional Analysis Chapter 11 Pipeline Biologic Drugs Chapter 12 Competitive Landscape Chapter 13 Company Profiles - Abbott Laboratories - Amgen Inc. - Baxter International Inc. - Biogen Idec - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline plc. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/hj...ical_drugs

Perrigo Beats on Q4 Earnings and Sales, Provides Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 12:29PM CDT
Perrigo (PRGO) reported higher than expected earnings and revenues in the fourth quarter.

Biotech, Social Media Stocks Are Less Frothy Than Janet Yellen Thinks
at The Street - Thu Aug 14, 11:34AM CDT
A month after Fed Chair Janet Yellen's comments, ETFs covering both groups are pushing towards new highs on strong fundamental backdrops.

Perrigo Q4 Beats Estimates, But Guidance Misses
at Investor's Business Daily - Thu Aug 14, 10:02AM CDT
Drugmaker Perrigo (PRGO) beat Wall Street's Q4 expectations Thursday morning, sending the stock up 6% on the stock market today even though its 2015 guidance missed estimates. Sales for the quarter ended June 28 rose 18% over the year-earlier quarter...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 85

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 65

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 38

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 30

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 34

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
ISDN Holdings: Leading APAC Automation with Innovation

Updated Category News Views 68

Pioneering Automation Intelligence in APAC Not every day you hear a company quietly revolutionizing an entire industry's landscape—but ISDN Holdings Limited is one of those rare players. Recognized by Frost & Sullivan for its top-tier customer value leadership, ISDN is making waves across the Asia-Pacific's industrial scene with its integrated industrial automation...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 105

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Max y Noelia Explore Trade at 9th CIIE in Shanghai

Updated Category News Views 23

Influencers at the Heart of Global Trade Exploration Makin' their debut on the big stage of the 9th China International Import Expo (CIIE), Mexican influencers Max y Noelia found themselves caught in a whirlwind of trade and cultural exchanges over in Shanghai. These digital mavens aren't just snapping selfies. Nope, they're capturing the very essence of international...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 189

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 67

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading

Top 5 Most Recently Viewed Articles

Rogers 5G Network Achieves Top Reliability Rankings in Canada

Updated Category News Views 293

Rogers Communications Recognition for 5G Reliability Rogers Communications has recently achieved a significant milestone, being recognized as the most reliable 5G wireless network in the country. This recognition comes from umlaut, a respected global leader in independent benchmarking. With this award, Rogers reaffirms its commitment to providing exceptional network...

Continue Reading
Cable Insurance Partners with TruckerCloud for Telematics Growth

Updated Category News Views 179

Cable Insurance Partners with TruckerCloud for Telematics Growth Cable Insurance, known for its commitment to commercial auto insurance, has formed a strategic alliance with TruckerCloud, a prominent telematics provider. This partnership is set to revolutionize Cable's telematics efforts, focusing on integrating real-time driving insights, streamlining claims processes,...

Continue Reading
Osisko Development Secures $24.2 Million in Funding via Placement

Updated Category News Views 256

Osisko Development’s Major Funding Achievement Osisko Development Corp. is thrilled to report the successful completion of the first tranche of its non-brokered private placement. This strategic move has garnered approximately US$24.2 million through the issuance of 13,426,589 units at a price of US$1.80 per unit. These funds mark a significant advancement for the...

Continue Reading
Anywhere Real Estate Inc. Celebrates 14 Years of Ethics in Business

Updated Category News Views 167

Anywhere Real Estate Inc. Recognized for Ethical Leadership Anywhere Real Estate Inc. (NYSE: HOUS), a leader in residential real estate services, proudly announced its recognition as one of the 2025 World’s Most Ethical Companies for the 14th consecutive year. This accolade highlights the company’s unwavering commitment to ethical practices, setting it apart in an...

Continue Reading
Stifel Affirms Buy Rating for STAAR Surgical Amid Market Challenges

Updated Category News Views 78

Stifel Affirms Strong Support for STAAR Surgical Recently, Stifel renewed its Buy rating for STAAR Surgical (NASDAQ:STAA), setting a target price of $44.00 per share. This upbeat assessment comes even amid broader market challenges. By analyzing various data points from China's refractive sector, Stifel suggests that the second half of 2024 could show signs of recovery...

Continue Reading